Primary diseases in t-AML patients
| Primary disease . | No. of patients . | % . |
|---|---|---|
| Solid cancers | 142 | 71 |
| Cancers of females | ||
| Breast | 74 | 52 |
| Cervix | 4 | 3 |
| Uterus | 2 | 1 |
| Ovary | 1 | 1 |
| Cancers affecting men | ||
| Prostate | 9 | 6 |
| Testis | 9 | 6 |
| Cerebral cancers | ||
| Glioma | 3 | 2 |
| Head and neck cancers | ||
| Thyroid | 12 | 8 |
| Larynx | 1 | 1 |
| Hypopharynx | 1 | 1 |
| Vocal cord | 1 | 1 |
| Thoracic cancers | ||
| Lung | 2 | 1 |
| Mediastinal | 2 | 1 |
| Abdominal cancers | ||
| Gastrointestinal | 10 | 7 |
| Kidney | 3 | 2 |
| Bladder | 1 | 1 |
| Skin cancers | ||
| Melanoma | 4 | 3 |
| Others | 1 | 1 |
| Bone cancers | ||
| Ewing sarcoma | 1 | 1 |
| Soft-tissue tumors | ||
| Histiocytoma | 1 | 1 |
| Hematologic malignancies | 55 | 27.5 |
| NHL | 25 | 46 |
| Hodgkin lymphoma | 20 | 36 |
| MDS* | 6 | 11 |
| ALL | 2 | 4 |
| AML† | 1 | 1.5 |
| MPN | 1 | 1.5 |
| Autoimmune diseases | 3 | 1.5 |
| Multiple sclerosis | 2 | 67 |
| Rheumatologic | 1 | 33 |
| Primary disease . | No. of patients . | % . |
|---|---|---|
| Solid cancers | 142 | 71 |
| Cancers of females | ||
| Breast | 74 | 52 |
| Cervix | 4 | 3 |
| Uterus | 2 | 1 |
| Ovary | 1 | 1 |
| Cancers affecting men | ||
| Prostate | 9 | 6 |
| Testis | 9 | 6 |
| Cerebral cancers | ||
| Glioma | 3 | 2 |
| Head and neck cancers | ||
| Thyroid | 12 | 8 |
| Larynx | 1 | 1 |
| Hypopharynx | 1 | 1 |
| Vocal cord | 1 | 1 |
| Thoracic cancers | ||
| Lung | 2 | 1 |
| Mediastinal | 2 | 1 |
| Abdominal cancers | ||
| Gastrointestinal | 10 | 7 |
| Kidney | 3 | 2 |
| Bladder | 1 | 1 |
| Skin cancers | ||
| Melanoma | 4 | 3 |
| Others | 1 | 1 |
| Bone cancers | ||
| Ewing sarcoma | 1 | 1 |
| Soft-tissue tumors | ||
| Histiocytoma | 1 | 1 |
| Hematologic malignancies | 55 | 27.5 |
| NHL | 25 | 46 |
| Hodgkin lymphoma | 20 | 36 |
| MDS* | 6 | 11 |
| ALL | 2 | 4 |
| AML† | 1 | 1.5 |
| MPN | 1 | 1.5 |
| Autoimmune diseases | 3 | 1.5 |
| Multiple sclerosis | 2 | 67 |
| Rheumatologic | 1 | 33 |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; and NHL, non-Hodgkin lymphoma.
MDS treated with decitabine, cyclophosphamid, azacitidine, or chemotherapy (unspecified).
t-AML after 9 years of treatment of de novo AML.